MedTrace Logo

Use of KC706 for the Treatment of Pemphigus Vulgaris

NCT00606749 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-06-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether KC706 is effective in the prevention and healing of blisters in patients with pemphigus vulgaris, while the patient remains on stable doses of corticosteroids and/or immunosuppressants.

Conditions

  • Pemphigus Vulgaris

Interventions

DRUG

KC706

300 mg once daily (QD) for 12 weeks.

Sponsors & Collaborators

  • Kemia, Inc

    lead INDUSTRY

Principal Investigators

  • Victoria Werth, MD · University of Pennsylvania

  • Bruce Strober, MD · NYU MEDICAL CENTER

  • Francisco Kerdel, MD · Florida Academic Dermatology Centers

  • Michael Kolodney, MD · University of California, Los Angeles

  • Neil Korman, MD · University Hospitals Cleveland Medical Center

  • Amit Pandya, MD · University of Texas Southwestern Medical Center

  • David Rubenstein, MD, PhD · University of North Carolina, Chapel Hill

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606749 on ClinicalTrials.gov